Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol for severe pneumonia in ICU
NCT05663905Phase 4Completed
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ambroxol in pneumonia (2 arms), sponsored by Universiti Kebangsaan Malaysia. Primary endpoint: Rate of resolution of severe pneumonia at 2 weeks. Started Jan 2023; status: completed.
02
Drugs
ambroxol
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT05663905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663905.